Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/31/25 | AstraZeneca (AZN) | AZD0780 for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
3/31/25 | Vaxcyte (PCVX) | VAX-24 for Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial) | Subscribers Only | Subscribers Only | Subscribers Only |
3/31/25 | Corcept Therapeutics (CORT) | Relacorilant for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
3/30/25 | Eli Lilly (LLY) | Lepodisiran for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
3/29/25 | Novo Nordisk (NVO) | Rybelsus for Cardiovascular Disease | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion (Emerging Markets) |
03/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
03/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
03/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
03/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Patient Enrollment Completed |